The importance of protein biomarkers in drug development: A roundtable discussion

Protein biomarkers provide a dynamic and real-time window into human biology and disease. They are increasingly used across all stages of the drug development pipeline, from early phase biomarker discovery, understanding mechanisms of action, to patient stratification and label expansion.

Join us for a virtual pharma roundtable discussion and learn how three experts are using protein biomarkers, and how biomarkers have contributed to their drug development work.

Key learning objectives

  • Learn how protein biomarkers are used across different stages of the drug development process
  • Discover what challenges protein biomarkers help overcome and how they have contributed to accelerating drug development

Who should attend?

Anybody working in drug discovery and development in pharma, biotech, or academia

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Speakers

Katerina Pardali
Katerina Pardali
Senior Scientific Director<br>AM-Pharma</p>
Michael D. Howell
Michael D. Howell
Co-Founder<br>Galileo Biosystems and Mountaineer Biosciences</p>
Magnus Althage
Magnus Althage
Director | Head of Translational Strategy team Translational Science & Experimental Medicine Early Cardiovascular, Renal and Metabolism Biopharmaceuticals<br>AstraZeneca</p>
Blake Forman
Blake Forman
Content Creator, SelectScience

Links

Tags